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CC BY-NC-ND license (http://creativeBackground/Purpose: Mutations in the tet oncogene family member 2 gene (TET2) are
frequently found in adult patients with acute myeloid leukemia (AML). Reports of TET2 muta-
tions in children are limited. We assessed the prevalence of TET2 mutations in Taiwanese chil-
dren with AML and analyzed their prognosis.
Methods: Between 1997 and 2010, a total of 69 consecutive children with AML were enrolled at
the National Taiwan University Hospital. The analysis for TET2 mutations was performed using
direct sequencing. Clinical characteristics and overall survival (OS) were compared between
patients with and without TET2 alterations.
Results: Intronic and missense mutations were identified. No nonsense or frameshift mutations
were observed. Two putative disease-causing missense mutations (S609C and A1865G) were
identified in one patient. We estimated the prevalence of TET2 mutations in the current pa-
tient population to be 1.4%. The most common polymorphism was I1762V (45%), followed by
V218M (12%), P29R (6%), and F868L (6%). Patients with polymorphism I1762V had an increasedave no conflicts of interest relevant to this article.
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an Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
802 M.-J. Li et al.10-year survival rate compared with patients without I1762V (48.4% vs. 25.7%, p Z 0.049) by
Chi-square test; OS was not different when examined using the KaplaneMeier method
(p Z 0.104).
Conclusion: The prevalence of TET2 mutations in children with AML compared with adults with
AML was lower and less complex. Patient prognosis associated with TET2 mutations in children
requires further investigation.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Acute myeloid leukemia (AML) is a phenotypically and
genetically heterogeneous disease affecting 10e15% of
pediatric patients with malignancies.1 In the past decade,
molecular studies have identified an increasing panel of
genetic markers associated with AML. These markers
enhance risk stratification, modify treatment strategy, and
improve patient prognosis.2
Myeloid leukemogenesis is a multistep process and the
classic two-hit model must be modified to account for novel
classes of mutant disease alleles, most notably mutations in
epigenetic modifiers. These include mutations in the genes
encoding tet methylcytosine dioxygenase 2 (TET2), iso-
citrate dehydrogenase 1 (IDH1), IDH2, additional sex
combs-like 1 (ASXL1), enhancer of zeste homologue 2
(EZH2), and DNA methyltransferase 3A (DNMT3A).3 TET2 is
a DNA methylation regulator that normally converts 5mC to
5hmC, an intermediate event leading to demethylation.4,5
Deletion of TET2 in vivo results in increased hematopoiet-
ic stem cell (HSC) self-renewal and development of myeloid
skewing in differentiation.6
TET2 mutations are found in 7e23% of adults with AML
and have demonstrated a correlation with patient
prognosis.7e12 TET2 mutations appear to be associated
with poor prognosis as determined by overall survival in
adult Taiwanese patients with AML with intermediate-risk
cytogenetics.8 Other reports similarly found that TET2
mutations are a poor prognostic indicator in cytogeneti-
cally normal AML patients with favorable genotypes.3,10,13
However, some reports have demonstrated no prognostic
effect of TET2 mutations in patients with primary
AML.9,11 A majority of TET2 mutations are heterozygous
in patients with leukemia where expression of the wild-
type allele has been retained, suggesting that TET2
functions as a haploinsufficient tumor suppressor in most
patients.7
The prevalence of TET2 mutations has been demon-
strated to be lower in pediatric patients with AML
(1.5e6%).5,14,15 The prognostic value of TET2 mutations in a
pediatric population is not easily determined due to the low
incidence of applicable cases. Kutny et al16 reported that
patients with TET2 mutations had lower event-free survival
compared with patients who are nonmutation carriers; this
difference was not statistically significant. The same group
also reported patients with I1762V polymorphism had bet-
ter overall survival.16 The role of TET2 mutations in AML
remains uncertain. Our study aimed to investigate TET2mutations in pediatric AML using bioinformatic tools to
further evaluate associations with pathogenic effects and
disease association.Methods
Patients and sample collection
Patients with AML who were younger than 18 years of age
and who had adequate cryopreserved bone marrow cells for
a complete mutation analysis were enrolled. All data were
collected between 1997 and 2010 at the National Taiwan
University Hospital. Age at onset, sex, initial white blood
cell count, blast percentage, hemoglobin level, platelet
count, karyotype results, immunophenotyping results,
treatment regimens, and outcomes were all retrospectively
obtained using patient chart data.
Except for patients with acute promyelocytic leukemia
(APL) who received the TPOG APL-97 or APL-2001 protocol,
all other patients received the TPOG AML 97A protocol. The
institutional ethics committee approved this study (No.
DMR100-IRB-035).DNA sequencing and TET2 mutation analyses
Genomic DNA was isolated from patients’ bone marrow
samples at AML diagnosis, and at complete remission (CR) or
relapse. Mutation analyses of TET2 (NM_001127208) were
performed using polymerase chain reaction (PCR) followed
by direct sequencing.11 The primer sequences and estimated
product lengths are listed in Table S1. Paired samples
(diagnosis and either CR or relapse) were compared in a total
of 32 patient samples. Missense mutations were regarded as
true only if they had been published previously or could be
verified in bone marrow samples in patients in remission in
the current study. Missense mutations existed both in diag-
nosis and samples from patients in CR were regarded as a
polymorphism. For those novel nonsynonymous mutations
without available CR samples, the pathogenic effects were
predicted by bioinformatic tools: PolymorphismPhenotyping
v2 (PolyPhen-2),17 MutPred,18 and Sorting Intolerant From
Tolerant (SIFT).19 When two or more bioinformatics ap-
proaches predicted pathological effects, the non-
synonymous alterations were considered to be putative
mutations. Variants within introns and synonymous variants
were not analyzed further.
Table 1 Patient characteristics.
Patient characteristic
Age, y, median (range) 9 (0e18)
Sex, n, (male/female) 38/31
Blasts bone marrow, %, median (range) 71 (1e95)
Blasts peripheral blood, %, median (range) 48 (0e99)
Subtype acute myeloid leukemia, n
M0 2
M1 15
M2 19
M3 5
M4 13
M5 9
M6 2
M7 2
Others 2
Cytogenetics, n
Normal 12
t(8;21) 11
t(15;17) 4
inv(16)/t(16;16) 6
Relapse 31
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When analyzing patient prognosis, only patients with
available active disease were enrolled. Clinical character-
istics were compared using a Chi-square test for binary
variables and a t-test for continuous variables between
patients with and without TET2 alterations. All eligible case
data were collected and analyzed to estimate overall sur-
vival (OS), which was measured from the start of treatment
to death from any cause. Survival curves were estimated
using the KaplaneMeier method. A value of p < 0.05 was
considered statistically significant.Figure 1 Location of TET2 missense mutations. Putative missens
marks and gray tick marks, respectively. Arrows indicate conserveResults
Patient profile
A total of 69 pediatric patients with AML, including 38 males
(55%) and 31 females (45%), were enrolled. The median age
was 9 years (range: 0.01e17.5 years). Thirty-one patients
(45%) experienced relapse. AM2L and AM1L accounted for
most (27.5% and 21.7%, respectively) patient cases. Twelve
patients (17%) had a normal karyotype. The French-Amer-
ican-British (FAB) classification and details of cytogenetic
changes in patients are listed in Table 1.
TET2 mutation analysis
A total of 103 bone marrow samples were analyzed for
mutations. Samples from the active disease stage were
collected from 66 patients (59 at diagnosis and 22 at
relapse). For the TET2 mutation analysis, only intronic
mutations and missense mutations were analyzed. There
were nine missense mutations, distributed across the whole
coding sequence, without hot spots (Figure 1). No nonsense
or frameshift mutations were identified.
Among 69 patients, 32 patients had samples collected
while in CR. Missense mutations P29R, V218M, R814C,
F868L, S1039L, and I1762V were classified as poly-
morphisms. The most common polymorphism was I1762V
(n Z 31, 45%), followed by V218M (n Z 8, 12%), P29R
(nZ 4, 6%), and F868L (nZ 4, 6%). For missense mutations
S609C, E1513G, and A1865G, no available sample from a
patient in CR was available. Details of published reports
describing polymorphisms and missense mutations is shown
in Table 2.10,20e33 According to published reports, E1513G
was classified as a polymorphism and A1865G was classified
as a true missense mutation. SIFT, Polyphen-2, and MutPred
predicted the nonsynonymous mutation S609C as being
pathologic; therefore, it was classified as a putative
missense mutation. We determined the prevalence of TET2
mutations in our patient population was 1.4% (1 of 69).e mutations and polymorphisms are represented by black tick
d regions (amino acids 1134e1444 and 1842e1921).
Table 2 Published polymorphisms and missense mutations of the TET2 gene.
In conserved area Not in conserved area
Polymorphism C1211Y,10 H1219Q,10 H1219R,10 L1248T,8 R1261C,10
C1263R,10 C1298Y,10 G1361D,10 F1368L,10 D1376E,10
H1382Y,10 I1873T,10 A1876V,10 A1882P,10 L1899P10
P29R,8,15 L34F,11,13,15 P174H,13 V218M,8,15
G355D,15 P363L,8,15 N767D,10 R814C,8
Y867H,11,13,15 F868L,8 P968R,15 E1010D,10
S1039L,8 E1073V,13 Q1084P,11,13 A1505T,10
E1513G,8 R1543P,8 G1697R,10 V1718L,10
L1721W,8,15 P1723S,13,15 I1762V,8,15
H1778R,8,15 V1833I10
Missense mutations C1135Y,13,25 E1137K,9 Y1148C,9 H1150D,20 L1151P,9,12
R1167T,21,25 I1175S,22,25 I1175V,23,25 C1193W,22,25
C1193Y,22,25 I1195V,24 K1197R,25 V1199I,11,25 S1204C,13,25
L1210P,25 L1212S,9,27 R1214W,13,22,25 R1216Q,24 H1219N,8
H1219L,26 H1219Y,22,25 C1221Y,9 W1233G,26 D1242V,13,25
Y1245S,13,25 G1256R,27 R1261C,10,13,25,26 R1261H,9,13,25
R1261L,25 C1263G,10 A1264P,10 T1270A,28 C1271G,20
C1271Y,11 C1271W,25 C1273S,10 G1275E,8,24,25 G1275W,9
G1282D,11,24,25 F1287L,21,25 P1287S,29 G1288S,8
G1288V,13,24 C1289T,27 C1289W,27 C1289F,22,25 C1289V,25
C1289Y,10 W1291R,8,25,29 S1292R,11,25 N1296G,27
C1298Y,10 K1299E,23,25 K1299G,30 K1299N,21,25 F1300C,26
R1302G,21,23,25 R1302Y,29 S1303R,26 S1303N,10
E1318G,21,25,29 L1322Q,8 L1322P,8,22,25 L1326S,8 M1333R,9
L1340P,8,25 A1344E,24 Q1348R,9 E1352K,9 A1355P,24
C1358G,25 R1359C,8,14,25 R1359S,22 R1359H,8,22,25
L1360R,24 G1361D,26 G1361S,22,25 R1366H,8,10,25
P1367S,21,25,29 F1368Y,11,25 G1370Q,31 G1370V,11,25
T1372I,25 C1374Y,8 H1380P,24 H1380Y,8e10,28 D1384V,22,25
M1388I,12 C1396W,25 L1398R,25 V1417F,10,13,25 D1427Y,8
R1440T,25 A1443V,16 D1844G,24 D1849E,9 S1853G,9
G1860R,22,25 G1861R,27 A1865G,8 H1868R,25 H1868D,8
H1868P,10 G1869W,23,25 S1870L,26 I1871S,8 L1872P,23,25
I1873T,8,13,21e23,25,26,29,30 C1875R,25 E1879A,22,25
H1881R,13,25,26 H1881Q,25 T1884A,9,22,25,26 P1889H,8
P1894H,10 R1896G,26 R1896S,25 R1896M,23 S1898F,23,25
V1900A,9,13,25 H1904Q,24 K1905E,26 G1913D,21,25,29
G1913V,22,25 A1919V13,25
C25R,20 L34F,12,27 P101H,11,25 S145N,10,13,25
Q232R,20 S282F,11,25 A308T,21,25 N312S,13,25
L346P,32 A394T,9 P399L,21,25 K423R,16
G429R,9 S460F,13,15,25 T492S,11,25 T497S,26
Q548L,11,25 H573Y,20 D666G,13,25 R686S,25
D688G,20 F760Y,14 N767D,16 G773V,11,25
E788L,28 R814H,9,16 S817T,21,25 S826I,28
Y867H,12,21,25 F868L,10,20 P941S,13,25
E1010D,16 S1039L,16 T1114N,25 T1114I,33
S1448N,9 R1467K,9 A1505T,9 V1557C,27
R1572Q,9 R1572W,26 P1575F,25 Y1579S,8
G1606A,20 R1660G,25 Y1696C,20
V1718L,9,13,16,25 R1739I,26 G1754R,9
H1757D,13,25 A1794G,26 L1801F,8
C1811R,13,25 Q1828L,13,25 R1926H,13,25
P1937S,24 P1941S,13,24,25 P1962L,9,10,24,25
R1966H,13,25 E1973K,16 R1974M,13,25
T1980I,9 R2000K13,25
804 M.-J. Li et al.Clinical manifestations
A comparison of clinical and biological variables between
patients with and without I1762V revealed no significant
difference between the two groups in terms of age, sex,
cytogenetics, blood parameters, and bone marrow blast
cells. Patients with polymorphism I1762V demonstrated
increased survival rate compared with patients without
I1762V (48.4% vs. 25.7%, p Z 0.049) by Chi-square test.
However, OS was not different for patients with and
without polymorphism I1762V using the Kaplan-Meier
method (p Z 0.104, Figure 2).Discussion
The current study analyzed TET2 mutations in 69 pediatric
AML patientsdonly intronic and missense mutations were
identified. Two putative disease-causing missense muta-
tions (S609C and A1865G) were identified in one patient.
The overall prevalence of TET2 mutations in our patientswas estimated to be 1.4% (1 of 69). Patients with poly-
morphism I1762V had better 10-year survival rate compared
with patients without I1762V (48.4% vs. 25.7%, p Z 0.049)
using the Chi-square test.
The prevalence of TET2 mutations in children with AML
was lower compared with adults with AML.5,13,15,23,24,27 In
the current study, identifying the TET2 mutation also
proved to be difficult. Moreover, no nonsense or frameshift
mutations were identified, which supported the hypothesis
that the TET2 mutation was less complex in children with
AML. Similar to the low prevalence of TET2 mutations in
children with AML, functional mutations of other
methylation-associated genes, such as IDH1 or IDH2 and
DNMT3A were notably less common (rare or absent) in pe-
diatric patients.5,34,35 Ho et al5 reported that 2 IDH2-
mutated patients harbored t(8;21), whereas IDH muta-
tions rarely occurred in adult AML patients with favorable
cytogenetic abnormalities.36 Liang et al14 described that
5.6% of children with AML harbor epigenetic regulator gene
mutations and only 1.5% of children had combined with
Class I or Class II mutations.
Figure 2 The overall survival (OS) of patients with and
without polymorphism I1762V. Patients with polymorphism
I1762V had an increased 10-year survival rate compared with
patients without I1762V (48.4% vs. 25.7%, pZ 0.049) using the
Chi-square test; OS was not different when examined using the
KaplaneMeier method (p Z 0.104).
TET2 mutations in leukemia 805It is notable that methylation-associated somatic muta-
tions arise in a substantially smaller proportion of pediatric
AML cases compared with adult AML cases.5,14 There are
likely other significant mechanisms of epigenetic dysregu-
lation in childhood AML patients that have not been eluci-
dated. For example, the MLL gene at 11q23, encoding a
histone methyltransferase with putative epigenetic func-
tion, is associated with the IDH2 mutation.5,37
To the best of our knowledge, we are currently reporting
the first use of bioinformatics tools to estimate the path-
ogenic value of TET2 missense mutations. Several studies
have applied similar methodology to predict the potentially
pathogenic effect of nonsynonymous single nucleotide
substitution; the tendency in computational mutation
analysis is to use a broad set of prediction methods in order
to attain reliable results.38,39 Published TET2 mutations and
polymorphisms were identified in the literature, which
provided the basis for estimated pathogenic effects using
bioinformatics tools: Polyphen-2, MutPred, and SIFT.
Although two or all of these bioinformatics tools predict
this missense mutation pathogenic, we assumed this
missense mutation is “true mutation”. The assumed results
were compared to realistic reported results and the cor-
relation was significant (pZ 0.005). The positive predictive
rate also can achieve 72%. Bioinformatics tools are an
economical and practical method to estimate a potential
pathogenic effect associated with TET2 mutations in chil-
dren with AML.
Published data on the prognostic value of TET2 muta-
tions in childhood AML are scarce. Only Kutny et al16 have
reported that the I1762V polymorphism was associated with
an improved prognosis. We also found patients with poly-
morphism I1762V tended to have an increased 10-year
survival rate compared with patients without poly-
morphism I1762V using the Chi-square test (48.4% vs. 25.7%,
pZ 0.049); although OS was not different using the Kaplan-
Meier method (p Z 0.104). TET2 mutations do not appear
to be correlated with clinical characteristics or prognosis in
childhood AML; however, due to the small number ofreported cases, it was difficult to draw any firm conclusions
regarding implications for prognosis.5,15,16
This current study had several limitations, including the
retrospective, single-center, observational study design
with a relatively small subject pool. However, considering
the patient population it can be considered a pilot study in
the pediatric AML space. Future studies should consider
focusing on differences in age-specific genetic and epige-
netic mechanisms of myeloid leukemogenesis, as these
differences may contribute to the development of targeted
therapies. Furthermore, using bioinformatics tools to pre-
dict a pathogenic effect should be used with caution
considering the variable response and lack of a clear asso-
ciation to AML outcomes.
In conclusion, the prevalence of TET2 mutations in pe-
diatric patients with AML is low and less complex compared
with adult AML. The prognostic value of the TET2 mutation
needs further investigation in order to confirm a role in
childhood AML.
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